Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 5
2020 6
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR. Nauck MA, et al. Cardiovasc Diabetol. 2019 Sep 3;18(1):116. doi: 10.1186/s12933-019-0921-2. Cardiovasc Diabetol. 2019. PMID: 31481069 Free PMC article. Clinical Trial.
A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.
Webb DR, Htike ZZ, Swarbrick DJ, Brady EM, Gray LJ, Biglands J, Gulsin GS, Henson J, Khunti K, McCann GP, Waller HL, Webb MA, Sargeant JA, Yates T, Zaccardi F, Davies MJ. Webb DR, et al. Diabetes Obes Metab. 2020 Jul;22(7):1187-1196. doi: 10.1111/dom.14023. Epub 2020 Apr 1. Diabetes Obes Metab. 2020. PMID: 32157772 Free article. Clinical Trial.
14 results